Anna Drynda

Ms. Anna Drynda

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ADAnna Drynda
Anna Drynda
APAgnieszka Padjas
Agnieszka Padjas
KWKrzysztof Wójcik
Krzysztof Wójcik
Radosław DziedzicRadosław Dziedzic
Radosław Dziedzic
GBGrzegorz Biedroń
Grzegorz Biedroń
Stanislawa Bazan-SochaStanislawa Bazan-Socha
Stanislawa Bazan-Socha
Objective. To characterize the eosinophilic granulomatosis with polyangiitis (EGPA) population from the POLVAS registry depending on ANCA status and diagnosis onset, including their comparison with the granulomatosis with polyangiitis (GPA) subset with elevated blood eosinophilia (min. 400/μl) (GPA HE) to develop a differentiating strategy. Methods. A retrospective analysis of the POLVAS registry. Results. The EGPA group comprised 111 patients. The ANCA‐positive subset (n = 45 [40.54%]) did not differ from the ANCA‐negative one in clinics. Nevertheless, cardiovascular manifestations were more common in ANCA‐negative patients than in those with anti‐myeloperoxidase (MPO) antibodies (46.97% vs. 26.92%, p = 0.045). Patients diagnosed before 2012 (n = 70 [63.06%]) were younger (median 41 vs. 49 years, p < 0.01), had higher blood eosinophilia at diagnosis (median 4,946 vs. 3,200/μl, p < 0.01), and more often ear/nose/throat (ENT) and cardiovascular involvement. GPA HE comprised 42 (13.00%) out of 323 GPA cases with reported blood eosinophil count. Both GPA subsets had a lower prevalence of respiratory, cardiovascular, and neurologic manifestations but more often renal and ocular involvement than EGPA. EGPA also had cutaneous and gastrointestinal signs more often than GPA with normal blood eosinophilia (GPA NE) but not GPA HE. The model differentiating EGPA from GPA HE, using ANCA status and clinical manifestations, had an AUC of 0.92, sensitivity of 96%, and specificity of 95%. Conclusion. Cardiovascular symptoms were more prevalent in the ANCA‐negative subset than in the MPO‐ANCA‐positive one. Since EGPA and GPE HE share similarities in clinics, diagnostic misleading may result in an inappropriate therapeutic approach. Further studies are needed to optimize their differentiation and tailored therapy, including biologics.

29 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ADAnna Drynda
Anna Drynda
MSMarcin Surmiak
Marcin Surmiak
Stanislawa Bazan-SochaStanislawa Bazan-Socha
Stanislawa Bazan-Socha
KWKatarzyna Wawrzycka-Adamczyk
Katarzyna Wawrzycka-Adamczyk
MKMariusz Korkosz
Mariusz Korkosz
KWKrzysztof Wójcik
Krzysztof Wójcik
Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) is a heterogeneous group of small-vessel vasculitides, characterized by the presence of antibodies binding to myeloperoxidase (MPO) and proteinase-3 (PR3) found in neutrophil granules. Apart from being the target of ANCA, neutrophils actively contribute to the vicious cycle of inflammation and vascular damage in AAV. On the other hand, platelets have recently been recognized as essential for thrombosis and as inflammatory effectors that collaborate with neutrophils, reinforcing the generation of reactive oxygen species (ROS) and the formation of neutrophil extracellular traps (NETs) in those diseases. Neutrophils exhibit morphological and functional heterogeneity in AAV, reflecting the complexity of their contribution to disease pathogenesis. Since long-term immunosuppression may be related to serious infections and malignancies, there is an urgent need for reliable biomarkers of disease activity to optimize the management of AAV. This review summarizes the current understanding of the role of neutrophils and platelets in the pathogenesis of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), focusing on their crosstalk, and highlights the potential for identifying novel biomarkers relevant for predicting the disease course and its relapses.

21 October 2025 in Viruses
Verified
Journal Article
Open access
PDF file
AMAleksandra Matyja-Bednarczyk
Aleksandra Matyja-Bednarczyk
Radosław DziedzicRadosław Dziedzic
Radosław Dziedzic
ADAnna Drynda
Anna Drynda
AGAda Gradzikiewicz
Ada Gradzikiewicz
MBMonika Bociąga-Jasik
Monika Bociąga-Jasik
Stanislawa Bazan-SochaStanislawa Bazan-Socha
Stanislawa Bazan-Socha
The SARS-CoV-2 pandemic presents a broad clinical spectrum from asymptomatic cases to severe respiratory failure with high mortality. Severe COVID-19 is characterized by immune dysregulation, including lymphopenia and alterations in the counts of T, B, and NK cells in peripheral blood. Due to the limited data on long-term outcomes related to immune dysregulation, we aimed to analyze immunologic features at baseline in severe and mild COVID-19 cases and assess follow-up characteristics associated with later mortality and long-COVID signs. We included adult patients consecutively hospitalized with COVID-19 between June and November 2020 at the University Hospital in Kraków, corresponding to the first and second waves of COVID-19 in Poland. We enrolled only those who had been thoroughly assessed in terms of clinic and laboratory data, including immunological workups, and survived the acute phase of the disease. In 2025, between February and April (median time of follow-up: 54 months), we conducted a telephone questionnaire on long-COVID symptoms among survivors who had given their consent. Statistical analyses were performed to compare groups with severe and mild disease in terms of dysregulation in lymphocyte subpopulations and the follow-up outcomes. The study included 103 COVID-19 patients, comprising 53 severe (based on the need for at least high-flow nasal oxygen therapy) and 50 mild cases, with no differences in age, sex, and body mass index. Severe COVID-19 patients compared to mild cases had lower CD3+ T cells (count and percentage), CD4+ T cells (count and percentage), CD8+ T cells (count), and NK cells (count), but higher CD19+ B cells (percentage) at baseline (p < 0.05, all). At the time of follow-up, we evaluated 80 patients (77.7% of the baseline participants), with 23 (22.3%) patients lost to follow-up. Among patients analyzed in the follow-up, 23 (28.8%) had died, and 29 of the 57 survivors (50.9%) reported persistent long-COVID symptoms. Patients who died had significantly lower baseline counts of CD3+ T cells (377 vs. 655 cells/µL), CD4+ T cells (224 vs. 372 cells/µL), CD8+ T cells (113 vs. 188 cells/µL), and NK cells (118 vs. 157 cells/µL) compared to survivors (p < 0.05, all). Notably, the percentage of CD19+ B cells was higher in deceased individuals (19.2% vs. 13.5%; p = 0.049). In contrast, we did not document differences in baseline immunological data among survivors with and without long-COVID signs. Our study suggests that dysregulation in lymphocyte subpopulations during the COVID-19 acute phase may be associated with increased late mortality, but not with the persistence of long-COVID symptoms.

23 July 2025 in Psychiatria Polska
Verified
Journal Article
Open access
BMBartłomiej Matejko
Bartłomiej Matejko
ADAnna Drynda
Anna Drynda
KCKatarzyna Cyranka
Katarzyna Cyranka
AJAnna Juza
Anna Juza
KNKatarzyna Nabrdalik
Katarzyna Nabrdalik
TKTomasz Klupa
Tomasz Klupa
Cel pracy: The initiation of reimbursement for intermittently scanned continuous glucose monitoring (isCGM)/ continuous glucose monitoring (CGM) for those 26 and older could greatly benefit people with type 1 diabetes (PwT1D). The aim of the study was to assess changes in quality of life, metabolic control, fear of hypoglycemia and selected psychological parameters after 3 months of implementation of the isCGM/CGM in PwT1D aged 26 and above.Metoda: The study involved 57 PwT1D from five diabetology centers. To be included in the study, each participant had to be at least 26 years old, have a minimum of two years of diabetes history. Participants completed a set of validated questionnaires including the FSH-II, DDS, PSS10, DTSQs, WHO-5, PAID, DBQ, and a sociodemographic survey. They also downloaded pump/glucometer data and underwent HbA1c measurement at the beginning and again at the end of the study.Wyniki: PwT1D reported higher treatment satisfaction measured by DTSQs. Well-being assessment according to WHO-5 was also higher, and the level of diabetes burnout measured by DBQ, fear of hypoglycemia assessed by HFS-II significantly decreased. Diabetic distress measured by means of total score of DDS lowered. Participants scored also lower on PAID upon follow up. The HbA1c level after three months of using the CGM system was significantly lower.Wnioski: The use of isCGM/CGM, even during relatively short observation, leads to improved quality of life, reduced fear of hypoglycemia and diabetes burnout, and lower HbA1c levels in PwT1D over the age of 26 who were naïve to this technology.

1 November 2024 in Nursing Reports
Verified
Journal Article
Open access
PDF file
DMDorota Mizera
Dorota Mizera
Radosław DziedzicRadosław Dziedzic
Radosław Dziedzic
ADAnna Drynda
Anna Drynda
AMAleksandra Matyja-Bednarczyk
Aleksandra Matyja-Bednarczyk
APAgnieszka Padjas
Agnieszka Padjas
Stanislawa Bazan-SochaStanislawa Bazan-Socha
Stanislawa Bazan-Socha
Background/Objectives: Inborn errors of immunity (IEI) encompass various congenital disorders, resulting in immunity defects and recurrent infections. Home-based subcutaneous immunoglobulin replacement therapy (scIgRT) is the best treatment option for those with primary antibody deficiency (PAD). However, the lack of standardized procedures in patient training remains a challenge. Our study investigates nurses’ practice and perspectives, aiming to identify areas for improvement in at-home scIgRT practice. Methods: We prepared a structured survey regarding scIgRT, including needle choice experience and perception of adverse events, and distributed it among qualified nurses involved in patient training and scIgRT supervising. Results: We included 56 nurses with a median age of 50 years. Among them, 67.9% represented adult care providers, while 32.1% supervised IgRT in children. Most respondents (83.9%) used the classic or assisted with hyaluronidase scIgRT preparations. Single-channel needles were administered most commonly (85.7%). The needle length was mostly chosen solely by a nurse (57.1%) or in cooperation with the patient (23.2%). Next, 9 mm and 12 mm needles were used most often (92.9% and 78.6%, respectively). As expected, the 6 mm needle was more frequently applied for children compared to adults (n = 16, 88.9% vs. n = 11, 28.9%, p < 0.001), while 12 mm was primarily used in adults (n = 35, 92.1% vs. n = 9, 50.0%, p < 0.001). Visual skin fold assessment was the basis for the needle selection (58.9%), followed by the injection site rule (26.8%) or a choice between two available needle types for thinner or thicker patients (25.0%). Results of this survey indicate that, according to nurses’ opinions presented in this survey, the needle length could be associated with local scIgRT adverse events, such as side needle leakage or local burning. Yet, it was likely unrelated to general adverse signs, such as headaches or dizziness. Most respondents (66.1%) indicated that, even if local adverse events occur, patients are reluctant to change scIgRT preparation or needle length. Most participants (69.6%) reported that the optimal administration technique needs to be discussed with the patient before and during scIgRT. Conclusions: This study sheds light on scIgRT practice in Poland, emphasizing deficiency in needle selection technique. Future research should focus on standardized training and advanced needle selection procedures on patient outcomes, investigating the correlation between needle strategies and adverse events, as well as the effectiveness of scIgRT.

21 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TITeresa Iwaniec
Teresa Iwaniec
Radosław DziedzicRadosław Dziedzic
Radosław Dziedzic
PKPiotr Kuszmiersz
Piotr Kuszmiersz
ADAnna Drynda
Anna Drynda
MSMagdalena Szuścik
Magdalena Szuścik
Stanislawa Bazan-SochaStanislawa Bazan-Socha
Stanislawa Bazan-Socha
Fabry disease (FD) is an ultrarare X-linked lysosomal storage disorder, resulting in the generalized cell accumulation of glycosphingolipids. Patients with FD are at increased risk of thromboembolic events. In 34 clinically stable FD patients (n = 17 [50%] men) and 34 controls matched by age, sex, and body mass index, we assessed the thrombin generation profile in plasma, using the calibrated automated thrombogram, in relation to clinical disease characteristics and laboratory parameters. FD patients were characterized by a 17.6% increase in endogenous thrombin potential (ETP) and a 9.8% higher thrombin peak (p = 0.009 and p = 0.008, respectively) compared to controls. They also had significantly elevated platelet counts (by 20.1%), factor VIII activity (by 50.6%), and fibrinogen levels (by 20.0%). A multiple regression model revealed that higher ETP in FD was independently determined by increased platelet counts, C-reactive protein, and fibrinogen, accounting for 39% of ETP variability. Comparison with controls of the same sex showed increased thrombin generation parameters only in FD men. In conclusion, FD patients exhibit an unfavorable altered thrombin generation profile, suggesting an increased risk of thrombosis. Further prospective studies are needed to determine whether enhanced thrombin generation can predict cardiovascular events in this population.